The good news continues to roll in for ResMed. Philips (big competitor) has suspended sleep apnea device sales in the US.

They’ve been bedeviled by issues for many months now, and the brand damage simply translates into more market share for RMD.

This follows on from the strong quarterly result, see our note from last week here.

Overall, at least in the first few years of GLP-1s reaching hyperscale (imagine them getting to a market share of 1/3rd, that sort of thing) CPAP demand should be complementary. If you enter the medical market place seeking a treatment for weight, with OSA as a comorbidity, the doctor will do three things 1) bloods (checking for diabetes) 2) the prescription/direction you are after (the GLP-1 drug) c) treat-your-highly-likely-to-be-present OSA.

Below is Mick Farrell, CEO, presenting evidence on GLP-1 users OSA equipment usage after starting GLP-1 treatment.

Important Information: This document has been prepared by Aequitas Investment Partners ABN 92 644 165 266 (“Aequitas”, “our”, “we”), a Corporate Authorised Representative (no. 1284389) of C2 Financial Services, (Australian Financial Services Licensee no. 502171), and is for distribution within Australia to wholesale clients and financial advisers only.

This document is based on information available at the time of publishing, information which we believe is correct and any opinions, conclusions or forecasts are reasonably held or made as at the time of its compilation, but no warranty is made as to its accuracy, reliability or completeness. To the extent permitted by law, neither Aequitas nor any of its affiliates accept liability to any person for loss or damage arising from the use of the information herein.

Please note that past performance is not a reliable indicator of future performance.

General Advice Warning: This document has been prepared without taking into account your objectives, financial situation or needs, and therefore you should consider its appropriateness, having regard to your objectives, financial situation and needs. Before making any decision about whether to acquire a financial product, you should obtain and read the relevant Product Disclosure Statement (PDS) or Investor Directed Portfolio Service Guide (IDPS Guide) and consider talking to a financial adviser.

Taxation warning: Any taxation considerations are general and based on present taxation laws and may be subject to change. Aequitas is not a registered tax (financial) adviser under the Tax Agent Services Act 2009 and investors should seek tax advice from a registered tax agent or a registered tax (financial) adviser if they intend to rely on this information to satisfy the liabilities or obligations or claim entitlements that arise, or could arise, under a taxation law.